NCT07142954RecruitingPhase 3
Epidemiology and Biomarker Study in Alzheimer's Disease
A Longitudinal, Prospective Epidemiology Study in Alzheimer's Disease: Assessing Neurocognitive and Biomarker Changes and Health Outcomes in Individuals at Risk for Symptoms of Alzheimer's Disease (ANCHOR-AD)
Source: ClinicalTrials.gov · Last updated 7 Jul 2026
Brief summary (registry, in English)
Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 3400 (estimated)
- First submitted
- 20 Aug 2025
- Start date
- 25 Aug 2025
- Primary completion date
- Jul 2033
- Lead sponsor
- Eli Lilly and Company
- Diseases
- Alzheimer disease
- NCT number
- NCT07142954
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 3400
- From 25 Aug 2025 to the primary completion date, Jul 2033
- 4 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Are currently enrolled or have previously participated in any Alzheimer's Disease (AD)-related study involving an investigational drug intervention.
- Are currently using or have previously used prescription medications for treatment of mild cognitive impairment (MCI) or dementia such as amyloid targeting therapy (that is, lecanemab, donanemab, aducanumab), cholinesterase inhibitors (for example, benzgalantamine, donepezil, galantamine, rivastigmine), and memantine.
Other illness
- Have a history or diagnosis of cognitive impairment, or significant other neurodegenerative disease that can affect cognition.
Other
- Have seen a doctor about memory concerns.
Who the study is looking for
- The participant must self-report unimpaired cognition.
- The participant must have adequate literacy, vision, and hearing for neuropsychological assessments at the time of screening.
Age in the registry: 55 years to 75 years · Sex: All · Accepts healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The University of Tokyo Hospital Coordinator of this site? Confirm its status | Bunkyō City | Japan | Recruiting |
| Souseikai Sumida Hospital Coordinator of this site? Confirm its status | Tokyo | Japan | Recruiting |
| Higashi Shinjuku Clinic Coordinator of this site? Confirm its status | Tokyo | Japan | Recruiting |
| Care Access - Houston Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.